Targeted Therapeutics for Cancer and Ophthalmology

TRC105

TRC105 is a novel, clinical stage antibody to endoglin, which is a protein that is overexpressed on endothelial cells and is essential for angiogenesis, the process of new blood vessel formation.  TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, hepatocellular carcinoma and colorectal cancer, in combination with VEGF inhibitors. Multiple Phase 1 and Phase 2 clinical trials of TRC105 as a single agent have been completed. Currently, TRC105 is being investigated in multiple clinical trials in combination with other agents, including Avastin® and other VEGF inhibitors.   In clinical trials to date, TRC105 has been generally well tolerated as a single agent and in combination with VEGF inhibitors.  In addition, Santen Pharmaceutical Co., Ltd., is developing TRC105 as a treatment for wet age-related macular degeneration ("AMD"), the leading cause of blindness in the western world.

TRC105 Scientific Presentations:

2016 CTOS Meeting, TRC105 + Votrient Angiosarcoma Poster
2016 ESMO Congress, TRC105 + Inlyta in RCC Final Phase 1b Poster
2016 ESMO Congress, Phase 2b TRAXAR Trials in Progress Poster
2016 ASCO Meeting, TRC105 + Votrient in Sarcoma Phase 1b/2 Poster
2016 ASCO Meeting, TRC105 + Avastin in Refractory GBM Phase 2 Poster
2016 AACR Meeting, TRC105 Pharmacodynamic Biomarker Studies Poster
2016 SGO Meeting, TRC105 + Avastin Choriocarcinoma Poster
2015 KCA Meeting, TRC105 + Inlyta Phase 1b Poster
2015 KCA Meeting, Phase 2b TRAXAR Trials in Progress Poster
2015 CTOS Meeting, TRC105 + Votrient Phase 1b Presentation
2015 World Congress on GTD, TRC105 + Avastin Abstract
2015 ASCO Meeting TRC105 + Nexavar Phase 1b Poster
2015 ASCO Meeting TRC105 + Votrient Phase 1b Poster
2015 ASCO Meeting TRC105 + Avastin in RCC Phase 2b NCI Poster
2015 AACR Meeting – preclinical poster, Dual Targeting of VEGF and Endoglin
2015 GU ASCO Meeting TRC105 + Inlyta Phase 1b Poster
2015 GI ASCO Meeting TRC105 + Nexavar Phase 1/2 Poster
2014 ESMO Meeting TRC105 in Ovarian Cancer Poster
2014 ASCO Meeting TRC105 + Avastin Phase 1b Biomarker Poster
2014 AACR Meeting TRC105 + Avastin Phase 1b PK Poster
2014 GI ASCO Meeting TRC105+ Nexavar Phase 1b Poster
2013 EORTC-NCI-AACR Meeting TRC105+Avastin Ph 1b Imaging Markers Poster
2013 AACR Meeting – CD105 – A Therapeutic Target for Sarcomas
2013 ASCO Meeting TRC105 + Avastin Phase 1b Poster
2013 ASCO Meeting TRC105 + Xeloda Phase 1b Poster
2012 ASCO Meeting TRC105 Phase 1 PK poster
2012 ASCO Meeting TRC105 Phase 1/2 Prostate Cancer poster
2012 ASCO Meeting TRC105 + Avastin Phase 1b poster
2011 ASCO Meeting Phase 1 poster
2011 ASCO Meeting Phase 1 slide show
2011 ASCO Meeting Duke biomarker poster
2010 AACR Meeting – preclinical poster
2009 AACR Meeting – preclinical poster

TRC105 Journal Publications:

Duarte, Cancer Epidemiology, Biomarkers and Prevention, 2013
Gordon et al. An Open Label Phase 1b Dose Escalation Study of TRC105 with Bevacizumab. Clin Cancer Res 2014
Rosen et al. Endoglin for Targeted Cancer Treatment. CurrOncRep 2014
Liu el al. Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Medicine 2014
Nolan-Stevaux et al. Endoglin Requirements for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies PLOSone 2012
Rosen el al. A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer. ClinCanRes 2012

Copyright © TRACON Pharmaceuticals, Inc. 2015